These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31034795)

  • 1. New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
    Liu C; Fang Y
    Biochem Pharmacol; 2019 Sep; 167():58-63. PubMed ID: 31034795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins.
    Duan Y; Du A; Gu J; Duan G; Wang C; Gui X; Ma Z; Qian B; Deng X; Zhang K; Sun L; Tian K; Zhang Y; Jiang H; Liu C; Fang Y
    Cell Res; 2019 Mar; 29(3):233-247. PubMed ID: 30728452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
    Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
    Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-Ribosylation) in Age-Related Neurological Disease.
    McGurk L; Rifai OM; Bonini NM
    Trends Genet; 2019 Aug; 35(8):601-613. PubMed ID: 31182245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases.
    Park H; Kam TI; Dawson TM; Dawson VL
    Int Rev Cell Mol Biol; 2020; 353():1-29. PubMed ID: 32381174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Poly adenosine diphosphate-ribosylation and neurodegenerative diseases].
    Wang Y; Lu Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):100-106. PubMed ID: 32621411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.
    Ryan P; Xu M; Davey AK; Danon JJ; Mellick GD; Kassiou M; Rudrawar S
    ACS Chem Neurosci; 2019 May; 10(5):2209-2221. PubMed ID: 30985105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress.
    Hegedűs C; Virág L
    Redox Biol; 2014; 2():978-82. PubMed ID: 25460733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Biomolecular Condensates by Poly(ADP-ribose).
    Rhine K; Odeh HM; Shorter J; Myong S
    Chem Rev; 2023 Jul; 123(14):9065-9093. PubMed ID: 37115110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NADP
    Bian C; Zhang C; Luo T; Vyas A; Chen SH; Liu C; Kassab MA; Yang Y; Kong M; Yu X
    Nat Commun; 2019 Feb; 10(1):693. PubMed ID: 30741937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARkinson's: From cellular mechanisms to potential therapeutics.
    Lengyel-Zhand Z; Puentes LN; Mach RH
    Pharmacol Ther; 2022 Feb; 230():107968. PubMed ID: 34391789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose)polymerase-1 hyperactivation in neurodegenerative diseases: The death knell tolls for neurons.
    Narne P; Pandey V; Simhadri PK; Phanithi PB
    Semin Cell Dev Biol; 2017 Mar; 63():154-166. PubMed ID: 27867042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of glia in protein aggregation.
    Li Q; Haney MS
    Neurobiol Dis; 2020 Sep; 143():105015. PubMed ID: 32663608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribosylation) and neurodegenerative disorders.
    Basello DA; Scovassi AI
    Mitochondrion; 2015 Sep; 24():56-63. PubMed ID: 26196946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic Analysis of the Downstream Signaling Network of PARP1.
    Zhen Y; Yu Y
    Biochemistry; 2018 Jan; 57(4):429-440. PubMed ID: 29327913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases.
    Longhena F; Spano P; Bellucci A
    Handb Exp Pharmacol; 2018; 245():85-110. PubMed ID: 28965171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. POSCAbilities: The Application of the Prion Organotypic Slice Culture Assay to Neurodegenerative Disease Research.
    Pineau H; Sim V
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32698402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: Past, present, and future.
    Hu ML; Pan YR; Yong YY; Liu Y; Yu L; Qin DL; Qiao G; Law BY; Wu JM; Zhou XG; Wu AG
    Ageing Res Rev; 2023 Nov; 91():102078. PubMed ID: 37758006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases.
    Wu Y; Ma B; Liu C; Li D; Sui G
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.